Compare Amphastar Pharmaceuticals Inc (AMPH) vs Best Buy Co Inc (BBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Best Buy Co Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Best Buy Co Inc trades at $82.59 (market cap $17.37B). The key difference: Best Buy Co Inc is far larger — about 20.1× Amphastar Pharmaceuticals Inc's market cap, and Best Buy Co Inc pays a 4.66% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BBY | |
|---|---|---|
Market Cap | $863.95M | $17.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $90.17 |
52-Week Low | $16.87 | $55.52 |
Enterprise Value | $1.26B | $19.75B |
Dividend Yield | — | 4.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Best Buy (BBY) trades at $82.00, up 2.47% today, with a bearish technical signal and mixed sentiment. Recent earnings beats and a forward P/E of 15.19 suggest reasonable valuation, but revenue has declined from $51.8B in 2022 to $41.5B in 2025. The company is testing smaller store formats and appointed a new CFO in August 2026, aiming to stabilize operations amid leadership changes.
Outlook is cautious; analyst consensus is a Hold with a $81.69 price target. Opportunities include cost control and dividend yield, but risks involve persistent revenue pressure, competitive threats, and execution risks from management turnover. Net cash flow turned positive in 2025, yet margin compression remains a concern for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
